![Robert Kiss](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Michel Allé | M | 74 |
Université Libre de Bruxelles
| 27 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Yvan de Launoit | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.
Université Libre de Bruxelles
| 16 jaar |
Francis Darro | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.
Université Libre de Bruxelles
| 15 jaar |
Ugo Falcinelli | M | - |
Université Libre de Bruxelles
| 4 jaar |
Qiu Zhi Xue | M | 67 |
Université Libre de Bruxelles
| 6 jaar |
Tanguy Cornet | M | - |
Université Libre de Bruxelles
| 5 jaar |
Piotr Tyranowski | M | - |
Université Libre de Bruxelles
| 4 jaar |
Etienne van de Kerckhove | M | 60 |
Université Libre de Bruxelles
| 6 jaar |
Alain van Gelderen | M | 53 |
Université Libre de Bruxelles
| 6 jaar |
Robert Bury | M | - |
Université Libre de Bruxelles
| 4 jaar |
Herjan Coelingh Bennink | M | - |
Université Libre de Bruxelles
| 8 jaar |
Pedro de Boeck | M | 59 |
Université Libre de Bruxelles
| 4 jaar |
Stéphanie Vanden Broecke | F | - |
Université Libre de Bruxelles
| 3 jaar |
Jean-François Hoffelt | M | 62 |
Université Libre de Bruxelles
| 1 jaar |
Nourredine Chinek | M | - |
Université Libre de Bruxelles
| 4 jaar |
Tuan Van Nguyen | M | 54 |
Université Libre de Bruxelles
| 2 jaar |
Bo I. Nilsson | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Daniel Grossmann | M | 53 |
Université Libre de Bruxelles
| 5 jaar |
Aminata Kaké | F | 47 |
Université Libre de Bruxelles
| 4 jaar |
Steven D. Weitman | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Frederic Halkin | M | - |
Université Libre de Bruxelles
| 1 jaar |
Emmanuel Lacroix | M | - |
Université Libre de Bruxelles
| 4 jaar |
Alain Beyens | M | 63 |
Université Libre de Bruxelles
| 4 jaar |
Huong Giang Thi Luong | F | 57 |
Université Libre de Bruxelles
| 2 jaar |
Benoît Taymans | M | - |
Université Libre de Bruxelles
| 4 jaar |
Muriel de Lathouwer | F | 51 |
Université Libre de Bruxelles
| 4 jaar |
Ayuporn Karnasuta | F | - |
Université Libre de Bruxelles
| 2 jaar |
Filip Kegels | M | 58 |
Université Libre de Bruxelles
| 2 jaar |
Nazmul Karim Chowdhury | M | 74 |
Université Libre de Bruxelles
| 3 jaar |
Gaudiana Giusti | F | 61 |
Université Libre de Bruxelles
| 3 jaar |
Gonzalo Tradacete Gallart | M | - |
Université Libre de Bruxelles
| 5 jaar |
Ann J. Barbier | M | 59 |
Université Libre de Bruxelles
| 3 jaar |
André Boulanger | M | - |
Université Libre de Bruxelles
| 4 jaar |
Christian Pierre B van Schoote | M | 59 |
Université Libre de Bruxelles
| 4 jaar |
Thomas Spitaels | M | - |
Université Libre de Bruxelles
| 4 jaar |
Eric van Quaquebeke | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | 9 jaar |
Marc Hellemans | M | 51 |
Université Libre de Bruxelles
| 4 jaar |
Frédéric Zoller | M | - |
Université Libre de Bruxelles
| 4 jaar |
Sven Arne Andréasson | M | 72 |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Kristel Verleyen | F | 53 |
Université Libre de Bruxelles
| 3 jaar |
Amelie Coens | F | - |
Université Libre de Bruxelles
| 4 jaar |
Axel Miller | M | 58 |
Université Libre de Bruxelles
| 5 jaar |
Olivier Roger J. Majérus | M | 62 |
Université Libre de Bruxelles
| 1 jaar |
Dimitri Dimitriou | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Matthias de Raeymaeker | M | 49 |
Université Libre de Bruxelles
| 2 jaar |
Hennie R. Hoogenboom | M | - |
Université Libre de Bruxelles
| 4 jaar |
Antoine Duchateau | M | 70 |
Université Libre de Bruxelles
| 1 jaar |
Bruno Jean Edmond Lambert | M | 65 |
Université Libre de Bruxelles
| 3 jaar |
Jean-Philippe Waterschoot | M | 61 |
Université Libre de Bruxelles
| 4 jaar |
Keith Bragman | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Wilfried van Langenaeker | M | - |
Université Libre de Bruxelles
| 4 jaar |
Didier Malherbe | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Christiane Verhaegen | F | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | 5 jaar |
Alain Parthoens | M | 64 |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Didier Georges | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Sandrine Evrard | F | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Mathieu Francois Pierre Pasture | M | - |
Université Libre de Bruxelles
| 1 jaar |
Erik M. van Mulligen | M | - |
Université Libre de Bruxelles
| 2 jaar |
Marc Josz | M | 66 |
Université Libre de Bruxelles
| 2 jaar |
Christian Leclercq | M | - |
Université Libre de Bruxelles
| 4 jaar |
Louis Martens | M | 62 |
Université Libre de Bruxelles
| 4 jaar |
Robert P. Swinnen | M | - |
Université Libre de Bruxelles
| 4 jaar |
Marc Wahba | M | - |
Université Libre de Bruxelles
| 4 jaar |
Frank van Vynckt | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Jos Sluys | M | 61 |
Université Libre de Bruxelles
| 4 jaar |
Genco Sanli | M | - |
Université Libre de Bruxelles
| 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
België | 66 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Robert Kiss
- Persoonlijk netwerk